Santen Pharmaceutical Co., Ltd.

Other

Inspire Pharmaceuticals, Inc.

Katsuhiko Nakata

Masatsugu Nakamura

Teruo Nishida

Yoichi Kawashima

Shiro Mita

Takashi Hamano

Tsutomu Fujihara

Hiromi Fujita

Masaaki Kageyama

The present invention provides healing promoters for skin wounds such as rupture, abrasion, surgical incision, skin ulcer and burn. Coexistence of Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH(SEQ ID NO:) or Phe-Gly-Leu-Met-NH(SEQ ID NO:) with insulin-like growth factor-I exhibits a remarkable promotive action on healing the skin wounds. Accordingly, combined administration of at least one of the substance P analogs and pharmaceutically acceptable salts thereof with the insulin-like growth factor exhibits a promotive effect on epidermal extension and a promotive effect on healing the skin wounds.

Skin wound healing promoters

Based on research for compounds that can display a corneal epithelial migration promoting effect in ophthalmology, the present invention provides P2Y receptor agonist corneal epithelial migration promoters, such as phosphoric acid compounds having an adenosyl group, uridyl group, xanthosyl group, guanosyl group, or thymidyl group, or their salts, with excellent corneal epithelial migration promoting effects.

Ectocornea extension promoters

The object of the present invention is to find new effects of natriuretic peptides in an ophthalmological field. The present invention provides eyedrops for promoting lacrimal secretion or for treating keratoconjunctival disorders containing the natriuretic peptide as active ingredient. The natriuretic peptides are atrial natriuretic peptides (ANP), brain natriuretic peptides (BNP) and C-type natriuretic peptides (CNP). Typical examples of the keratoconjunctival disorder are dry eye, corneal erosion and corneal ulcer.

Lacrimal secretion promoters or eye drops for treating keratoconjunctival failure containing as the active ingredient natriuretic peptides

Remedies for ocular diseases

An ophthalmic composition for treating corneal disorder which comprises Phe-Gly-Leu-Met-NH,or a pharmaceutically acceptable salt thereof as an active ingredient. Also a composition for treating corneal disorders, particularly a composition for promoting corneal epithelial migration, which comprises Phe-Gly-Leu-Met-NH,or a pharmaceutically acceptable salt thereof and an insulin-like growth factor I. Preferably the compositions are in the form of ophthalmic formulations.

Ophthalmic drug compositions

Remedy for keratoconjunctival diseases

Substituted butaneolides and butane lactams, and pharmaceutical use

Growing community of inventors

Ikoma, Japan

Katsuhiko Nakata